Net Income (Loss) Attributable to Parent in USD of ABVC BIOPHARMA, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Abvc Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Abvc Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$1.25M, a 216% decline year-over-year.
  • Abvc Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$5.08M, a 11.5% decline year-over-year.
  • Abvc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$4.9M, a 37% increase from 2023.
  • Abvc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.79M, a 52.6% increase from 2022.
  • Abvc Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$16.4M, a 27.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

ABVC BIOPHARMA, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$5.08M -$1.25M -$852K -216% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-03
Q2 2025 -$4.23M -$2.26M -$1.31M -140% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 -$2.91M -$842K +$1.99M +70.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-04-30
Q4 2024 -$4.9M -$732K -$348K -90.8% Oct 1, 2024 Dec 31, 2024 10-K 2025-04-15
Q3 2024 -$4.55M -$395K +$2.92M +88.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-03
Q2 2024 -$7.48M -$942K +$1.32M +58.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 -$8.8M -$2.83M -$1.01M -55.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-04-30
Q4 2023 -$7.79M -$383K +$4.48M +92.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-04-15
Q3 2023 -$12.3M -$3.32M +$387K +10.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$12.7M -$2.26M -$405K -21.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$12.3M -$1.82M +$4.17M +69.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-17
Q4 2022 -$16.4M -$4.86M +$3M +38.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$19.4M -$3.7M -$1.9M -105% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-15
Q2 2022 -$17.5M -$1.86M +$113K +5.71% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$17.6M -$6M -$4.8M -402% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$12.8M -$7.87M -$2.9M -58.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$9.94M -$1.81M +$325K +15.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$10.3M -$1.97M +$212K +9.73% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$10.5M -$1.2M +$114K +8.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$10.6M -$4.97M -$3.85M -345% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$6.74M -$2.13M -$801K -60.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$5.94M -$2.18M -$1.57M -255% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$4.37M -$1.31M -$436K -49.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$3.93M -$1.12M +$2.81M +71.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 -$6.75M -$1.33M -$642K -93.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-17
Q2 2019 -$6.1M -$614K +$122K +16.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-17
Q1 2019 -$6.22M -$873K -$160K -22.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-17
Q4 2018 -$6.06M -$3.93M -$3.55M -930% Oct 1, 2018 Dec 31, 2018 10-K 2020-05-15
Q3 2018 -$2.52M -$687K +$2.7M +79.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-18
Q2 2018 -$5.22M -$736K -$518K -238% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$4.7M -$714K -$457K -178% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-28
Q4 2017 -$4.24M -$381K -$171K -81.2% Oct 1, 2017 Dec 31, 2017 10-KT 2018-04-13
Q3 2017 -$4.07M -$3.39M -$2.78M -460% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$1.29M -$218K +$75.4K +25.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-20
Q1 2017 -$1.36M -$257K +$6.35M +96.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$7.72M -$210K +$3.29M +94% Oct 1, 2016 Dec 31, 2016 10-KT 2018-04-13
Q3 2016 -$11M -$604K -$289K -91.5% Jul 1, 2016 Sep 30, 2016 10-KT 2018-04-13
Q2 2016 -$10.7M -$293K -$292K Apr 1, 2016 Jun 30, 2016 10-Q 2018-03-19
Q1 2016 -$10.4M -$6.61M -$6.61M Jan 1, 2016 Mar 31, 2016 10-Q/A 2018-03-19
Q4 2015 -$3.82M -$3.5M -$2.47M -240% Oct 1, 2015 Dec 31, 2015 10-Q/A 2018-03-19
Q3 2015 -$1.35M -$316K -$292K -1258% Jul 21, 2015 Sep 30, 2015 10-KT 2018-04-13
Q2 2015 -$1.05M -$1.5K* -$1.47K Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-19
Q1 2015 -$1.05M $1.12K* +$1.15K Jan 1, 2015 Mar 31, 2015 10-Q 2015-06-05
Q4 2014 -$1.05M -$1.03M -$1.03M Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-23
Q3 2014 -$23.2K -$159K -117% Sep 19, 2014 Sep 30, 2014 10-K 2015-11-27
Q2 2014 $135K -$30* +$104K Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-19
Q1 2014 $31.7K -$30* +$104K Jan 1, 2014 Mar 31, 2014 10-Q 2015-06-05
Q4 2013 -$72.6K -$10* +$154K Oct 1, 2013 Dec 31, 2013 10-Q 2015-04-17
Q3 2013 -$226K $135K +$326K Jul 1, 2013 Sep 30, 2013 10-K 2015-04-17
Q2 2013 -$552K -$104K +$155K +60% Apr 1, 2013 Jun 30, 2013 10-Q 2015-04-17
Q1 2013 -$708K -$104K +$239K +69.6% Jan 1, 2013 Mar 31, 2013 10-Q 2015-04-17
Q4 2012 -$946K -$154K +$123K +44.5% Oct 1, 2012 Dec 31, 2012 10-Q 2015-04-17
Q3 2012 -$1.07M -$191K +$271K +58.7% Jul 1, 2012 Sep 30, 2012 10-K 2015-04-16
Q2 2012 -$1.34M -$259K +$556K +68.2% Apr 1, 2012 Jun 30, 2012 10-Q 2015-04-16
Q1 2012 -$1.9M -$343K -$826K -171% Jan 1, 2012 Mar 31, 2012 10-Q 2015-04-16
Q4 2011 -$1.07M -$277K +$147K +34.6% Oct 1, 2011 Dec 31, 2011 10-Q 2015-04-16
Q3 2011 -$1.22M -$462K Jul 1, 2011 Sep 30, 2011 10-K 2015-04-15
Q2 2011 -$815K -$606K -290% Apr 1, 2011 Jun 30, 2011 10-Q/A 2012-08-20
Q1 2011 $483K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15
Q4 2010 -$424K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-21
Q2 2010 -$209K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-09-08

ABVC BIOPHARMA, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$4.9M +$2.89M +37% Jan 1, 2024 Dec 31, 2024 10-K 2025-04-15
2023 -$7.79M +$8.64M +52.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-04-15
2022 -$16.4M -$3.58M -27.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-13
2021 -$12.8M -$2.25M -21.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$10.6M -$6.66M -169% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$3.93M +$2.13M +35.1% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
2018 -$6.06M -$1.82M -42.9% Jan 1, 2018 Dec 31, 2018 10-K 2020-05-15
2017 -$4.24M +$6.76M +61.5% Jan 1, 2017 Dec 31, 2017 10-K 2019-04-15
2016 -$11M -$11M -34000% Oct 1, 2015 Sep 30, 2016 10-KT 2018-04-13
2015 -$32.3K -$9.05K -38.9% Oct 1, 2014 Sep 30, 2015 10-K 2015-11-27
2014 -$23.2K +$203K +89.7% Oct 1, 2013 Sep 30, 2014 10-K 2015-11-27
2013 -$226K +$843K +78.8% Oct 1, 2012 Sep 30, 2013 10-K 2015-04-17
2012 -$1.07M +$149K +12.2% Oct 1, 2011 Sep 30, 2012 10-K 2015-04-16
2011 -$1.22M +$682K +35.9% Oct 1, 2010 Sep 30, 2011 10-K 2015-04-15
2010 -$1.9M Oct 1, 2009 Sep 30, 2010 10-K/A 2011-12-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.